Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (221-230 of 386) with videos related to

Pageof 39
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerA J Armstrong, M Häggman, W M Stadler, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
The Journal of Urology|November 9, 2019
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial CarcinomaVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Human Pathology|May 1, 2012
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomasAlcides Chaux, Luciana Schultz, Roula Albadine, et al.
The Prostate|June 25, 2016
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyMichael T Schweizer, Hao Wang, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancerJonathan W Simons, Michael A Carducci, Bahar Mikhak, et al.
Urology|May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, Christophe Massard, Mitchell E Gross, et al.
Pageof 39

Showing results (221-230 of 386) with videos related to

Sort By:
Pageof 39
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerA J Armstrong, M Häggman, W M Stadler, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
The Journal of Urology|November 9, 2019
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial CarcinomaVitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Human Pathology|May 1, 2012
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomasAlcides Chaux, Luciana Schultz, Roula Albadine, et al.
The Prostate|June 25, 2016
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyMichael T Schweizer, Hao Wang, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancerJonathan W Simons, Michael A Carducci, Bahar Mikhak, et al.
Urology|May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, Christophe Massard, Mitchell E Gross, et al.
Pageof 39